INOVIO Pharmaceuticals Inc. (NASDAQ: INO) announced its intention to offer shares of common stock and accompanying Series A and Series B warrants in an underwritten public offering. The biotechnology company plans to sell all securities in the proposed offering itself.

The company intends to grant the underwriter a 30-day option to purchase additional shares and warrants up to 15% of the securities offered under the same terms and conditions. Piper Sandler will serve as sole manager for the offering.

INOVIO operates as a biotechnology company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company is based in Plymouth Meeting, Pennsylvania.

The offering will proceed under a shelf registration statement filed with the Securities and Exchange Commission on November 9, 2023, which became effective on January 31, 2024. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the agency's website.

The company stated that the proposed offering remains subject to market conditions and provided no assurance regarding completion, timing, or final terms of the offering.